{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T10:35:23Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 23.3, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0952e-7a53-71a0-b707-f6e53c2d8775\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: isavuconazole\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 r", "usd": 0.0, "recall": true }, "codex": { "seconds": 78.1, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0952e-7a5d-7b03-a3af-2ee8a210530e\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: isavuconazole\nRegistry id: vr.tr.isavuconazole\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:49:29+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:32+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q6079042", "registryId": "vr.tr.isavuconazole", "name": "isavuconazole", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q6079042/", "model": { "registry_id": "vr.tr.isavuconazole", "name": "isavuconazole", "purpose": "Enable an agent to identify isavuconazole, assess the identity and fitness of a material or measurement, and determine which handling, analytical or pharmacological decisions its evidence supports.", "definition": "Isavuconazole is a fluorinated triazole antifungal compound that inhibits fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis, and is the active moiety delivered clinically by the prodrug isavuconazonium sulfate.", "scope_statement": "This model owns vr.tr.isavuconazole in PHY / PHY.MAT: the active antifungal substance, its material states, analytical identity and evidence-qualified biological properties. Isavuconazonium sulfate is its prodrug and a neighbouring substance, as described in the [FDA prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/207500s016%2C207501s016lbl.pdf).", "in_scope": [ "Chemical identity, stereochemistry and independently verified substance identifiers", "Isavuconazole sample composition, purity, impurities and material form", "Condition-dependent physical properties, stability and laboratory handling", "Analytical identification and quantification in material and biological matrices", "Antifungal activity, resistance and exposure relationships with their evidence limits", "Relations to its prodrug, medicinal products and applicable substance requirements" ], "out_of_scope": [ "The independent chemical identity and manufacturing specification of isavuconazonium sulfate", "Finished medicinal product formulations, packaging and administration instructions", "Patient-specific prescribing, dosing and treatment decisions", "Fungal species taxonomy and complete infection models", "Manufacturing plant operations and synthesis process models" ], "distinguishing_features": [ "Verify molecular connectivity and stereochemistry against an authenticated isavuconazole reference; an azole-class label alone does not establish identity.", "Distinguish measured isavuconazole from isavuconazonium and its sulfate salt rather than treating the names as synonyms.", "Determine whether a reported mass denotes actual isavuconazole or an isavuconazole-equivalent amount of prodrug.", "Separate an isolated isavuconazole sample from a medicinal product whose label refers to the active moiety.", "Require analyte-selective evidence that separates isavuconazole from related substances and degradation products." ], "characteristics": [ { "name": "Chemical identity and stereochemical match", "kind": "category", "unit_or_values": "Confirmed match | provisional match | mismatch | unresolved; reference structure and identifier authority", "why_it_matters": "Prevents substitution of the prodrug, another azole or a stereochemically different material." }, { "name": "Relationship to supplied substance", "kind": "relation", "unit_or_values": "Isolated substance | active moiety of prodrug | analyte in mixture | reference standard", "why_it_matters": "Determines what a sample or label actually represents." }, { "name": "Assay and reporting basis", "kind": "measurement", "unit_or_values": "% mass fraction or mg/g; as-is, dried or other explicitly defined basis", "why_it_matters": "Makes potency and purity results interpretable across samples." }, { "name": "Related substances and residual components", "kind": "measurement", "unit_or_values": "% or ppm by named impurity; water and residual solvents separately reported", "why_it_matters": "Supports fitness decisions without conflating chromatographic area with mass purity." }, { "name": "Physical form and phase", "kind": "state", "unit_or_values": "Observed phase; crystalline, amorphous or unresolved solid form; solvent or hydrate status where established", "why_it_matters": "Qualifies physical-property measurements and sample preparation." }, { "name": "Solubility under stated conditions", "kind": "measurement", "unit_or_values": "mg/mL or mol/L with solvent, pH, temperature and equilibration method", "why_it_matters": "Determines whether analytical and experimental solutions can be prepared reliably." }, { "name": "Stability and storage qualification", "kind": "state", "unit_or_values": "Within qualified conditions | excursion pending assessment | degraded | unknown", "why_it_matters": "Controls whether a stored sample remains fit for its intended use." }, { "name": "Matrix-specific isavuconazole concentration", "kind": "measurement", "unit_or_values": "ng/mL or mg/L; matrix, collection time and total or unbound basis required", "why_it_matters": "Prevents incomparable exposure measurements from being combined." }, { "name": "Antifungal susceptibility result", "kind": "measurement", "unit_or_values": "MIC in mg/L with organism, isolate, method, endpoint and interpretive standard version", "why_it_matters": "Preserves the conditions needed to interpret an activity result." }, { "name": "Hazard and regulatory evidence", "kind": "relation", "unit_or_values": "Substance-specific SDS or authority record with jurisdiction, revision date and applicability", "why_it_matters": "Prevents product warnings or prodrug classifications from being assigned automatically to this substance." } ], "affordances": [ "Resolve a substance record to isavuconazole using structure and identifier evidence.", "Accept, quarantine or reject a sample against a stated analytical-use specification.", "Select an evidence-supported solvent, preparation procedure and storage condition for a defined experiment.", "Normalize mass or concentration reports after establishing analyte identity and reporting basis.", "Compare antifungal measurements only when organism and assay conditions support comparison.", "Route clinical interpretation and product administration questions to linked models with the relevant evidence." ], "agent_conduct": { "may": [ "Identify isavuconazole by name, identifiers and documented properties, citing sources.", "Report approved uses and interactions from regulator-approved product information.", "Check a lot's certificate of analysis against its specification for its handler." ], "must_not": [ "Recommend a dose or a change of antifungal treatment for a particular patient.", "Supply or sell it outside lawful pharmaceutical channels.", "Release a lot that has failed its specification or lacks a certificate.", "Present it as a treatment for an infection it has not been approved for." ], "requires_human": [ "Any decision to start, stop or change a patient's antifungal therapy.", "Releasing or destroying a material lot." ] }, "ethics": { "considerations": [ "Invasive fungal infections are often fatal in vulnerable patients, so errors in supply or advice cost lives.", "Antifungal resistance makes careless use a public harm." ], "affected_parties": [ "Patients with invasive fungal infections", "Prescribers and pharmacists", "Manufacturing staff" ] }, "owners": { "steward": "The marketing authorization holder for each medicine; the national medicines regulator oversees it.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identity rests on the label, batch record and certificate of analysis, not appearance.", "Clinical products usually carry the prodrug name rather than isavuconazole itself." ], "failure_modes_and_hazards": [ "Drug interactions through liver enzymes can raise or lower levels of other medicines.", "Confusing the active moiety and the prodrug can lead to dosing errors.", "Liver injury and other adverse reactions require clinical monitoring." ], "standards_and_regulation": [ "ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, International Council for Harmonisation." ], "what_it_is_for": [ "Isavuconazole is encountered in pharmaceutical analysis and antifungal research as the active compound delivered clinically through the prodrug isavuconazonium sulfate.", "Laboratories measure it in biological samples and study its activity against fungi.", "Its identity must be distinguished from that of the prodrug when interpreting analytical results or pharmaceutical documentation." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q6079042: isavuconazole", "url": "https://www.wikidata.org/wiki/Q6079042", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Isavuconazonium", "url": "https://en.wikipedia.org/wiki/Isavuconazonium", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "isavuconazole-identity", "name": "Isavuconazole identity", "description": "Establish which molecular entity the registry entry and each associated record denote.", "rationale": "Active-moiety naming can obscure the difference between isavuconazole, its prodrug and a finished product.", "layers": [ { "id": "structure-and-identifiers", "name": "Structure and identifiers", "description": "Anchor names and database records to the same stereochemically specified substance.", "findings": [ { "id": "identity-anchor", "name": "Structure-backed identity", "description": "Require agreement between the reference structure, stereochemistry and identifier records before consolidating substance data.", "questions": [ { "text": "Which authoritative record establishes the molecular structure and stereochemistry of isavuconazole?", "kind": "definition", "id": "identity-anchor-q01" }, { "text": "Which CAS, PubChem and applicable EC identifiers resolve to that exact entity rather than its prodrug?", "kind": "provenance", "id": "identity-anchor-q02" } ] } ] }, { "id": "prodrug-and-product-boundaries", "name": "Prodrug and product boundaries", "description": "Maintain explicit relations between the active substance and records that refer to it indirectly.", "findings": [ { "id": "active-moiety-accounting", "name": "Active-moiety accounting", "description": "Distinguish substance identity from active-moiety equivalence in labels and measurements.", "questions": [ { "text": "Does the record denote isavuconazole itself, isavuconazonium, isavuconazonium sulfate or a formulated product?", "kind": "boundary", "id": "active-moiety-accounting-q01" }, { "text": "If an amount is expressed as isavuconazole equivalents, which documented conversion and rounding convention apply?", "kind": "measurement", "id": "active-moiety-accounting-q02" } ] } ] } ] }, { "id": "material-quality-and-form", "name": "Material quality and form", "description": "Describe the actual isavuconazole material available for analysis or experimentation.", "rationale": "A correct name does not establish sample purity, solid form or suitability as a reference material.", "layers": [ { "id": "sample-composition", "name": "Sample composition", "description": "Qualify the amount of isavuconazole and other components in a specific sample.", "findings": [ { "id": "assay-and-impurity-basis", "name": "Assay and impurity basis", "description": "Keep quantitative assay, related substances, water and residual solvents distinguishable.", "questions": [ { "text": "What is the measured isavuconazole content, and is it reported on an as-is, dried or solvent-free basis?", "kind": "measurement", "id": "assay-and-impurity-basis-q01" }, { "text": "Which methods distinguish stereochemical impurities, other related substances and residual components?", "kind": "measurement", "id": "assay-and-impurity-basis-q02" }, { "text": "Which certificate and acceptance criteria support this sample's intended use?", "kind": "provenance", "id": "assay-and-impurity-basis-q03" } ] } ] }, { "id": "phase-and-physical-properties", "name": "Phase and physical properties", "description": "Tie measured constants to the material form and experimental conditions.", "findings": [ { "id": "condition-qualified-properties", "name": "Condition-qualified properties", "description": "Record solubility and thermal behaviour without assuming that product or prodrug values describe isavuconazole.", "questions": [ { "text": "What evidence establishes the sample's phase, solid form and any solvent or water association?", "kind": "measurement", "id": "condition-qualified-properties-q01" }, { "text": "What solubility is measured at the stated solvent composition, pH and temperature?", "kind": "measurement", "id": "condition-qualified-properties-q02" }, { "text": "Do reported thermal values represent melting, decomposition or another transition, and is a boiling point experimentally meaningful?", "kind": "boundary", "id": "condition-qualified-properties-q03" } ] } ] } ] }, { "id": "analytical-recognition", "name": "Analytical recognition", "description": "Identify and quantify isavuconazole with methods appropriate to the specimen.", "rationale": "Bulk-material assays and biological measurements require different controls and can confuse the active analyte with related compounds.", "layers": [ { "id": "selectivity-and-reference-materials", "name": "Selectivity and reference materials", "description": "Establish that an analytical signal belongs to isavuconazole.", "findings": [ { "id": "analyte-confirmation", "name": "Analyte confirmation", "description": "Require reference traceability and demonstrated discrimination from plausible interferents.", "questions": [ { "text": "Which authenticated reference material anchors chromatographic, spectrometric or structural identification?", "kind": "provenance", "id": "analyte-confirmation-q01" }, { "text": "Can the method distinguish isavuconazole from prodrug, degradation products and matrix interferents?", "kind": "measurement", "id": "analyte-confirmation-q02" } ] } ] }, { "id": "quantification-and-specimen-integrity", "name": "Quantification and specimen integrity", "description": "Qualify measured concentrations through calibration and specimen handling.", "findings": [ { "id": "interpretable-concentration", "name": "Interpretable concentration", "description": "Attach matrix, analyte basis and validation limits to every concentration result.", "questions": [ { "text": "Which matrix, units and total or unbound analyte basis define this concentration?", "kind": "measurement", "id": "interpretable-concentration-q01" }, { "text": "What calibration range, uncertainty and quantification limit support the reported value?", "kind": "measurement", "id": "interpretable-concentration-q02" }, { "text": "Could sample handling, instability or prodrug conversion after collection change the measured isavuconazole concentration?", "kind": "boundary", "id": "interpretable-concentration-q03" } ] } ] } ] }, { "id": "antifungal-action-and-exposure", "name": "Antifungal action and exposure", "description": "Organize evidence connecting isavuconazole exposure to fungal effects.", "rationale": "An antifungal classification alone cannot support organism-specific activity or exposure interpretation.", "layers": [ { "id": "mechanism-and-susceptibility", "name": "Mechanism and susceptibility", "description": "Separate molecular mechanism evidence from isolate-level susceptibility observations.", "findings": [ { "id": "activity-evidence", "name": "Activity evidence", "description": "Make mechanism, organism coverage and resistance claims traceable to their experimental basis.", "questions": [ { "text": "Which primary evidence establishes the fungal target and downstream effects of isavuconazole?", "kind": "provenance", "id": "activity-evidence-q01" }, { "text": "For which species and isolates was activity measured, using which susceptibility method and endpoint?", "kind": "measurement", "id": "activity-evidence-q02" }, { "text": "Which resistance mechanisms or cross-resistance findings limit extrapolation from other azoles?", "kind": "boundary", "id": "activity-evidence-q03" } ] } ] }, { "id": "exposure-and-disposition", "name": "Exposure and disposition", "description": "Describe pharmacological relationships without turning a substance model into a prescribing protocol.", "findings": [ { "id": "exposure-interpretation", "name": "Exposure interpretation", "description": "Qualify disposition and exposure-effect evidence by species, population, sampling and study conditions.", "questions": [ { "text": "Which studies establish protein binding, metabolism and elimination of measured isavuconazole?", "kind": "provenance", "id": "exposure-interpretation-q01" }, { "text": "Which exposure measures correlate with antifungal effects, and in what experimental or clinical context?", "kind": "measurement", "id": "exposure-interpretation-q02" }, { "text": "When must a concentration interpretation be handed to a patient-specific treatment model?", "kind": "action", "id": "exposure-interpretation-q03" } ] } ] } ] }, { "id": "stewardship-and-use-constraints", "name": "Stewardship and use constraints", "description": "Determine whether an isavuconazole sample can be handled, retained or used under documented conditions.", "rationale": "Laboratory substance handling, biological safety evidence and medicinal-product requirements have distinct applicability.", "layers": [ { "id": "storage-and-laboratory-handling", "name": "Storage and laboratory handling", "description": "Connect sample form and use to stability evidence and applicable hazard information.", "findings": [ { "id": "qualified-handling", "name": "Qualified handling", "description": "Require substance-specific support for storage, solution lifetime and protective controls.", "questions": [ { "text": "Which storage and solution-use conditions have been demonstrated for this isavuconazole material?", "kind": "provenance", "id": "qualified-handling-q01" }, { "text": "Which current SDS, GHS classification and established exposure limits apply to the supplied form?", "kind": "provenance", "id": "qualified-handling-q02" }, { "text": "After a storage excursion or suspected degradation, which reassessment determines whether the sample can be used?", "kind": "action", "id": "qualified-handling-q03" } ] } ] }, { "id": "biological-and-regulatory-applicability", "name": "Biological and regulatory applicability", "description": "Preserve the boundaries around safety evidence and permitted uses.", "findings": [ { "id": "use-evidence-boundaries", "name": "Use evidence boundaries", "description": "Attach safety and regulatory claims to the studied entity, context and jurisdiction.", "questions": [ { "text": "Which evidence concerning cardiac repolarization, hepatic effects and drug interactions is attributable to isavuconazole exposure?", "kind": "provenance", "id": "use-evidence-boundaries-q01" }, { "text": "Does a cited authorization or restriction apply to isolated isavuconazole, its prodrug or a particular medicinal product?", "kind": "boundary", "id": "use-evidence-boundaries-q02" }, { "text": "What evidence is required before this specific sample may serve as a reference standard or experimental reagent?", "kind": "action", "id": "use-evidence-boundaries-q03" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recalled knowledge; no sources were consulted.", "Current jurisdiction-specific indications, contraindications and authorized age groups require verification against official product information.", "Purity specifications, solid forms, melting point, GHS classification and occupational exposure limits are not confidently recalled and are omitted." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of isavuconazole this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "isavuconazole", "note": "Names the active antifungal compound, distinct from its prodrug." }, { "scheme": "CAS Registry Number", "value_or_pattern": "241479-67-4", "note": "Identifies isavuconazole rather than isavuconazonium sulfate." }, { "scheme": "WHO Anatomical Therapeutic Chemical (ATC) classification", "value_or_pattern": "J02AC05", "note": "Classification within systemic triazole antifungals." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of isavuconazole this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-standards-and-regulation", "name": "Standards and regulation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "US Food and Drug Administration prescribing requirements apply to approved isavuconazonium sulfate medicines that deliver isavuconazole.", "European Union medicinal-product authorization and product information cover isavuconazonium sulfate medicines following European Medicines Agency assessment." ], "questions": [ { "id": "evidence-standards-and-regulation-q01", "text": "Which of these standards and regulation hold for the sense of isavuconazole this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Treatment of invasive aspergillosis through administration of its prodrug.", "Treatment of invasive mucormycosis through administration of its prodrug, subject to jurisdiction-specific indications.", "Laboratory testing of fungal susceptibility to antifungal agents." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of isavuconazole this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass", "typical_range": "437.47", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of isavuconazole this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Fungal resistance or reduced susceptibility can limit antifungal activity.", "Clinical exposure can cause liver injury.", "Clinical exposure can shorten the QT interval; familial short QT syndrome is a relevant contraindication.", "CYP3A-mediated drug interactions can alter isavuconazole exposure or the exposure of coadministered medicines.", "Hypersensitivity reactions can occur." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of isavuconazole this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Approved indications, age groups and conditions of use vary by jurisdiction.", "European authorization for mucormycosis has specified patients for whom amphotericin B is inappropriate; US indication wording differs." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of isavuconazole this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "isavuconazonium sulfate", "difference": "A water-soluble prodrug salt converted in the body to isavuconazole; it has a different chemical identity and molar mass." }, { "name": "voriconazole", "difference": "A distinct triazole antifungal with a different molecular structure and susceptibility spectrum; it does not provide equivalent activity against Mucorales." }, { "name": "posaconazole", "difference": "A distinct triazole antifungal with overlapping clinical uses but a different molecular structure, formulation profile and pharmacokinetics." }, { "name": "Cresemba", "difference": "A medicinal-product brand containing isavuconazonium sulfate, rather than the name of the isolated active compound." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of isavuconazole this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative structure and identifier records establish the exact isavuconazole entity, including stereochemistry and applicable CAS, PubChem and EC identifiers?", "Which primary measurements establish solid form, solubility and thermal behaviour for isolated isavuconazole rather than its prodrug or formulated products?", "What impurity specifications, stability data and reference-material qualifications are available for the intended sample grade?", "Which current susceptibility standards support organism-specific interpretation, and where do breakpoints or exposure targets remain unestablished?", "Which substance-specific hazard classifications, exposure limits and jurisdictional restrictions are documented, and which remain unavailable?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 35 } }